Therapy in RCDII: Rationale for Combination Strategies?

Area of Science:

• Gastroenterology
• Immunology
• Oncology

Background:

• Refractory coeliac disease type II (RCDII) is a severe autoimmune disorder with a high risk of malignant transformation, often considered an indolent lymphoma.
• RCDII is histologically defined by villous atrophy (Marsh III A-C) and a specific aberrant intraepithelial lymphocyte (IEL) population (>20% sCD3-CD7+iCD3+ IELs).
• These aberrant IELs are heterogeneous, with varying responses to cytokines like IL-15, and some exhibit monoclonal TCRγδ phenotypes, indicating complex immune dysregulation.

Purpose of the Study:

• To address the challenges posed by the heterogeneous nature of aberrant IELs in RCDII and their high risk of malignant transformation.
• To propose a novel therapeutic strategy for RCDII that accounts for cellular heterogeneity and aims for improved outcomes and EATL prevention.

Main Methods:

• Characterization of the aberrant IEL population in RCDII, including their immunophenotype (sCD3-CD7+iCD3+) and cytokine responsiveness (IL-15, common γ-chain cytokines).
• Review of existing treatment modalities for RCDII, including cladribine (2-CDA) and stem cell transplantation, and their limitations regarding malignant transformation.
• Hypothesizing a new combination therapy approach targeting downstream Jak-STAT signaling pathways alongside conventional treatment.

Main Results:

• The aberrant IEL population in RCDII is confirmed to be heterogeneous, with distinct subsets showing differential responses to cytokines.
• Current treatments like cladribine, while effective for symptoms and survival, do not fully mitigate the high risk of subsequent EATL development.
• The high rate of malignant transformation in cladribine-refractory cases underscores the need for more effective therapeutic strategies.

Conclusions:

• RCDII should be conceptualized as a pre-malignant condition or low-grade lymphoma requiring aggressive management.
• An upfront combination therapy integrating Jak-STAT pathway inhibition with conventional treatment (2-CDA) is proposed.
• This novel approach aims to effectively manage RCDII symptoms and significantly improve EATL prevention by addressing cellular heterogeneity.